COMPANY

History

  • 2023

    • 10

      Attended AACR-NCI-EORTC 2023

    • 06

      Attended BIO 2023 International Convention (BIO USA 2023)

    • 04

      Research service contract with Samsung Bioepis

    • 04

      Relocation of head office and R&D center (Songdo Technopark IT Center)

  • 2022

    • 07

      07 Research service contract with Inventage Lab

    • 04

      Research service contract with LG Chem

    • 01

      Cryo-EM Platform Krios(300kV) Operation

  • 2021

    • 07

      Research service contract with MirimGene

    • 06

      Cryo-EM Platform Aquilios 2, Glacios(200kV) Operation

    • 05

      Research service contract with eFlask

    • 02

      Fund Raising (Series A)

  • 2020

    • 11

      Selected for a National grant of Development of AI platform based first-in-class drug design to overcome drug-resistance of melanoma patients by Ministry of SMEs and Start Ups

    • 10

      Selected for a National grant of Drug development of colon cancer and rare diseases using artificial intelligence platforms by Ministry of SMEs and Start Ups

    • 08

      Certified as a Venture Business Company

    • 04

      Establishment of Company R&D Center

    • 04

      Company name changed to BaobabAiBIO Co., Ltd.

    • 04

      Move to Yonsei University International Campus at Songdo Incheon

    • 03

      Selected for BIG3(Bio, Health) Project by Ministry of SMEe and Startups

  • 2019

    • 11

      Inauguration of CEO In Sang Lee and CTO Kyoung Tai No(Each Representative)

    • 04

      Fund Raising from Geno Focus (Seed)

  • 2018

    • 07

      Selected for a National grant of Bio-SPC for development of therapeutic agents by Ministry of Science & ICT

    • 04

      Inauguration of CEO Kyoung Tai No

    • 04

      Establishment of Baobab Pharm Co., Ltd. at Yonsei University Seoul Korea